Explore the latest in ovarian cancer, including recent advances in epidemiology, screening, genetic testing, and management of the disease.
This observational study describes the prevalence of germline genetic testing in California and Georgia between 2013 and 2019 among patients diagnosed with cancer.
This Viewpoint explains the use of opportunistic salpingectomy, removal of the fallopian tubes for the primary prevention of ovarian cancer in a woman already undergoing pelvic surgery for another indication.
This nonrandomized phase 2 clinical trial examines the clinical activity of Olvi-Vec oncolytic immunotherapy and subsequent platinum-doublet chemotherapy with or without bevacizumab in women with platinum-resistant or -refractory ovarian cancers.
This cohort study examines the gender-specific COVID-19 case fatality risks among patients with a malignant neoplasm
This review summarizes the current and evolving treatment landscape for platinum-resistant ovarian cancer and highlights the development of promising novel compounds.
This retrospective cohort study assesses mortality and survival in premenopausal women with pregnancy-associated cancers, with a particular focus on cancers other than those of the breast.
This Viewpoint discusses the need for assessing the risk of hereditary breast and ovarian cancer in individuals seeking gender-affirming surgery and referring eligible patients to genetic counseling and testing services before surgery.
This case-control study pools and analyzes individual-level data from 8 Ovarian Cancer Association Consortium case-control studies to evaluate whether a polygenic score modifies the association of frequent aspirin use with ovarian cancer.
This cohort study assesses health care affordability, availability, and accessibility along with race and ethnicity in association with receipt of guideline-adherent care for ovarian cancer.
This diagnostic study determines whether the Ovarian-Adnexal Reporting and Data System (O-RADS) lexicon and the International Ovarian Tumor Analysis (IOTA) 2-step strategy can be used to stratify patients into risk groups.
A 62-year-old nulligravida woman had 10 months of progressive abdominal distension, diffuse abdominal pain, and 25-kg weight gain. She had no nausea or vomiting, hematochezia, or stool changes; pelvic and abdominal examination showed a large abdominal mass extending from the epigastrium to the pelvis but no other abnormalities; results of laboratory testing, including cancer antigen levels, were unremarkable. What is the diagnosis and what would you do next?
This nonrandomized controlled trial assesses responses associated with the combination of avelumab and talazoparib in patients with different tumor types and molecular subtypes.
This phase 2b nonrandomized controlled trial evaluates whether the combination of avelumab and talazoparib is effective in patients with pathogenic BRCA1/2 or ATM alterations, regardless of tumor type.
This diagnostic study of women with epithelial ovarian carcinoma assesses whether computed tomography–based radiomic features can differentiate histologic subtypes of epithelial ovarian carcinoma.
This comparative effectiveness study assesses the numbers needed to treat in targeted trials of agents for newly diagnosed ovarian cancer.
This cross-sectional study evaluates the features of oncology clinical trials that use germline genetic data.
This case-control study examines the potential association between white blood cell BRCA1 promoter methylation and subsequent risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.
This cohort study assesses the clinical outcomes and multiomic profiles of tumor specimens from women with advanced-stage ovarian cancer.
This Viewpoint evaluates factors introduced by the overturn of Roe v Wade that will further complicate the complex, multidisciplinary decision-making involved in treating patients with pregnancy-associated cancer.
Customize your JAMA Network experience by selecting one or more topics from the list below.